Delivery of anti-platelet-endothelial cell adhesion molecule single-chain variable fragment-urokinase fusion protein to the cerebral vasculature lyses arterial clots and attenuates postischemic brain edema

Journal of Pharmacology and Experimental Therapeutics

Volumn 321, Issue 3, 2007, Pages 947-952

  Danielyan, Kristina ^a   Ding, Bi Sen ^a   Gottstein, Claudia ^c   Cines, Douglas B ^b   Muzykantov, Vladimir R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c University of California   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPLATELET ENDOTHELIAL CELL ADHESION MOLECULE; CD31 ANTIGEN; CELL ADHESION MOLECULE; HYBRID PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOT; BLOOD CLOT LYSIS; BRAIN ARTERY; BRAIN BLOOD VESSEL; BRAIN EDEMA; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FIBRINOLYSIS; INFLAMMATION; MALE; MOUSE; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; THROMBOSIS;

ANIMALS; ANTIGENS, CD31; BLOOD-BRAIN BARRIER; BRAIN; BRAIN CHEMISTRY; BRAIN EDEMA; CEREBELLUM; CEREBROVASCULAR CIRCULATION; DRUG DELIVERY SYSTEMS; FIBRINOLYSIS; IMMUNOGLOBULIN FRAGMENTS; INJECTIONS, INTRA-ARTERIAL; INTRACRANIAL THROMBOSIS; MALE; MICE; MICE, INBRED C57BL; PRODRUGS; RECOMBINANT FUSION PROTEINS; TEMPORAL LOBE; THROMBOLYTIC THERAPY; URINARY PLASMINOGEN ACTIVATOR;

EID: 34248591331     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.120535     Document Type: Article

References (40)

1. Armstead WM, Nassar T, Akkawi S, Smith DH, Chen XH, Cines DB, and Higazi AA (2006) Neutralizing the neurotoxic effects of exogenous and endogenous tPA. Nat Neurosci 9:1150-1155.
2. Atochin DN, Murciano JC, Gursoy-Ozdemir Y, Krasik T, Noda F, Ayata C, Dunn AK, Moskowitz MA, Huang PL, and Muzykantov VR (2004) Mouse model of microembolic stroke and reperfusion. Stroke 35:2177-2182.
3. Christofidou-Solomidou M, Kennel S, Scherpereel A, Wiewrodt R, Solomides CC, Pietra GG, Murciano JC, Shah SA, Ischiropoulos H, Albelda SM, et al. (2002) Vascular immunotargeting of glucose oxidase to the endothelial antigens induces distinct forms of oxidant acute lung injury: targeting to thrombomodulin, but not to PECAM-1, causes pulmonary thrombosis and neutrophil transmigration. Am J Pathol 160:1155-1169.
4. Danilov SM, Gavrilyuk VD, Franke FE, Pauls K, Harshaw DW, McDonald TD, Miletich DJ, and Muzykantov VR (2001) Lung uptake of antibodies to endothelial antigens: key determinants of vascular immunotargeting. Am J Physiol 280:L1335-L1347.
5. Ding BS, Gottstein C, Grunow A, Kuo A, Ganguly K, Albelda SM, Cines DB, and Muzykantov VR (2005) Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature. Blood 106:4191-4198.
6. Everts M, Kok RJ, Asgeirsdottir SA, Melgert BN, Moolenaar TJ, Koning GA, van Luyn MJ, Meijer DK, and Molema G (2002) Selective intracellular delivery of dexamethasone into activated endothelial cells using an E-selectin-directed immunoconjugate. J Immunol 168:883-889.
7. Falati S, Patil S, Gross PL, Stapleton M, Merrill-Skoloff G, Barrett NE, Pixton KL, Weiler H, Cooley B, Newman DK, et al. (2006) Platelet PECAM-1 inhibits thrombus formation in vivo. Blood 107:535-541.
8. Fujise K, Revelle BM, Stacy L, Madison EL, Yeh ET, Willerson JT, and Beck PJ (1997) A tissue plasminogen activator/P-selectin fusion protein is an effective thrombolytic agent. Circulation 95:715-722.
9. Giri R, Shen Y, Stins M, Du Yan S, Schmidt AM, Stern D, Kim KS, Zlokovic B, and Kalra VK (2000) beta-Amyloid-induced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1. Am J Physiol 279:C1772-C1781.
10. Hennan JK, Hong TT, Shergill AK, Driscoll EM, Cardin AD, and Lucchesi BR (2002) Intimatan prevents arterial and venous thrombosis in a canine model of deep vessel wall injury. J Pharmacol Exp Ther 301:1151-1156.
11. Holvoet P, Laroche Y, Lijnen HR, Van Cauwenberge R, Demarsin E, Brouwers E, Matthyssens G, and Collen D (1991) Characterization of a chimeric plasminogen activator consisting of a single-chain Fv fragment derived from a fibrin fragment D-dimer-specific antibody and a truncated single-chain urokinase. J Biol Chem 266:19717-19724.
12. Jackson CV, Bailey BD, and Shetler TJ (2000) Pharmacological profile of recombinant, human activated protein C (LY203638) in a canine model of coronary artery thrombosis. J Pharmacol Exp Ther 295:967-971.
13. Johnston SC (2002) Clinical practice. Transient ischemic attack. N Engl J Med 347:1687-1692.
14. Kang DW, Chalela JA, Dunn W, and Warach S (2005) MRI screening before standard tissue plasminogen activator therapy is feasible and safe. Stroke 36:1939-1943.
15. Liberatore GT, Samson A, Bladin C, Schleuning WD, and Medcalf RL (2003) Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke 34:537-543.
16. Lo EH, Dalkara T, and Moskowitz MA (2003) Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 4:399-415.
17. Maas M, Stapleton M, Bergom C, Mattson DL, Newman DK, and Newman PJ (2005) Endothelial cell PECAM-1 confers protection against endotoxic shock. Am J Physiol 288:H159-H164.
18. Melchor JP and Strickland S (2005) Tissue plasminogen activator in central nervous system physiology and pathology. Thromb Haemost 93:655-660.
19. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, Pettigrew LC, Adams HP Jr, et al. (2001) A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 345:1444-1451.
20. Murciano JC, Harshaw D, Neschis DG, Koniaris L, Bdeir K, Medinilla S, Fisher AB, Golden MA, Cines DB, Nakada MT, et al. (2002) Platelets inhibit the lysis of pulmonary microemboli. Am J Physiol 282:L529-L539.
21. Muro S and Muzykantov VR (2005) Targeting of antioxidant and anti-thrombotic drugs to endothelial cell adhesion molecules. Curr Pharm Des 11:2383-2401.
22. Muro S, Wiewrodt R, Thomas A, Koniaris L, Albelda SM, Muzykantov VR, and Koval M (2003) A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1. J Cell Sci 116:1599-1609.
23. Muzykantov VR, Atochina EN, Kuo A, Barnathan ES, Notarfrancesco K, Shuman H, Dodia C, and Fisher AB (1996a) Endothelial cells internalize monoclonal antibody to angiotensin-converting enzyme. Am J Physiol 270:L704-L713.
24. Muzykantov VR, Barnathan ES, Atochina EN, Kuo A, Danilov SM, and Fisher AB (1996b) Targeting of antibody-conjugated plasminogen activators to the pulmonary vasculature. J Pharmacol Exp Ther 279:1026-1034.
25. Muzykantov VR, Christofidou-Solomidou M, Balyasnikova I, Harshaw DW, Schultz L, Fisher AB, and Albelda SM (1999) Streptavidin facilitates internalization and pulmonary targeting of an anti-endothelial cell antibody (platelet-endothelial cell adhesion molecule 1): a strategy for vascular immunotargeting of drugs. Proc Natl Acad Sci USA 96:2379-2384.
26. Pannell R and Gurewich V (1987) Activation of plasminogen by single-chain urokinase or by two-chain urokinase - a demonstration that single-chain urokinase has a low catalytic activity (pro-urokinase). Blood 69:22-26.
27. Peter K, Graeber J, Kipriyanov S, Zewe-Welschof M, Runge MS, Kubler W, Little M, and Bode C (2000) Construction and functional evaluation of a single-chain antibody fusion protein with fibrin targeting and thrombin inhibition after activation by factor Xa. Circulation 101:1158-1164.
28. Pluskota E, Soloviev DA, and Plow EF (2003) Convergence of the adhesive and fibrinolytic systems: recognition of urokinase by integrin alpha Mbeta 2 as well as by the urokinase receptor regulates cell adhesion and migration. Blood 101:1582-1590.
29. Rijken DC, Barrett-Bergshoeff MM, Jie AF, Criscuoli M, and Sakharov DV (2004) Clot penetration and fibrin binding of amediplase, a chimeric plasminogen activator (K2 tu-PA). Thromb Haemost 91:52-60.
30. Rosenberg RD and Aird WC (1999) Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med 340:1555-1564.
31. Sakharov DV and Rijken DC (1995) Superficial accumulation of plasminogen during plasma clot lysis. Circulation 92:1883-1890.
32. Scherpereel A, Rome JJ, Wiewrodt R, Watkins SC, Harshaw DW, Alder S, Christofidou-Solomidou M, Haut E, Murciano JC, Nakada M, et al. (2002) Platelet-endothelial cell adhesion molecule-1-directed immunotargeting to cardiopulmonary vasculature. J Pharmacol Exp Ther 300:777-786.
33. Thomas GR, Thibodeaux H, Errett CJ, Badillo JM, Keyt BA, Refino CJ, Zivin JA, and Bennett WF (1994) A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding. Stroke 25:2072-2078, discussion 2078-2079.
34. Topol EJ, Byzova TV, and Plow EF (1999) Platelet GPIIb-IIIa blockers. Lancet 353:227-231.
35. Verstraete M, Bounameaux H, de Cock F, Van de Werf F, and Collen D (1985) Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans. J Pharmacol Exp Ther 235:506-512.
36. Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, and Lipton SA (1998) Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med 4:228-231.
37. Waugh JM, Kattash M, Li J, Yuksel E, Kuo MD, Lussier M, Weinfeld AB, Saxena R, Rabinovsky ED, Thung S, et al. (1999) Gene therapy to promote thromboresistance: local overexpression of tissue plasminogen activator to prevent arterial thrombosis in an in vivo rabbit model. Proc Natl Acad Sci USA 96:1065-1070.
38. Yepes M, Sandkvist M, Moore EG, Bugge TH, Strickland DK, and Lawrence DA (2003) Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest 112:1533-1540.
39. Zhang Y and Pardridge WM (2005) Delivery of β-galactosidase to mouse brain via the blood-brain barrier transferrin receptor. J Pharmacol Exp Ther 313:1075-1081.
40. Zivin JA (1999) Thrombolytic stroke therapy: past, present, and future. Neurology 53:14-19.